July 25, 2017
Lilly posts revenue growth in the second quarter
Lilly delivered strong revenue growth in the second quarter, building on the momentum of Trulicity, Taltz and the other new products in its portfolio.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
July 25, 2017
Cellectis granted European RNA-guided endonucleases patent, more patents on the way
Cellectis, a French clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), on Tuesday announced a patent grant by the European Patent Office, for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.
July 25, 2017
Amryt’s Lojuxta reduces bad cholesterol
Amryt Pharma has published a long-term extension study of Lojuxta in treating a rare, genetic, life-threatening disease, Homozygous Familial Hypercholesterolaemia (HoFH), which followed patients for up to 5.7 years results, showed Lojuxta as being highly effective in lowering LDL-C levels, with acceptable tolerability and no new safety signals.
July 24, 2017
Valneva cleared for the only currently active clinical stage Lyme vaccine candidate
Valneva on Monday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its Lyme disease vaccine candidate VLA15.
July 24, 2017
Ablynx in warrant exercise
Belgian company Ablynx said Monday that it has issued an additional 19.833 common shares, in exchange for €121.444.
July 24, 2017
Sanofi, Regeneron seek European approval for approval in Europe for Dupinext to treat adults with atopic dermatitis
Sanofi and Regeneron Pharmaceuticals, on Friday announced that the European Medicine Agency`s Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Dupixent.
July 22, 2017
The first targeted treatment for newly diagnosed certain Leukemia in the EU
Novartis on Friday said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Rydapt (midostaurin) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive.
July 22, 2017
GSK submits EU filing for Relvar Ellipta extension
GlaxoSmithKline and Innoviva have asked the European Medicines Agency (EMA) to extend the use of Relvar Ellipta, a once-daily fluticasone furoate/vilanterol-based (FF/VI) inhaled corticosteroid (ICS) / combination, in patients already adequately controlled on an ICS/LABA combination.
July 21, 2017
Strong FDA workforce for patients’ benefits, scientists invited to join
The new efforts the FDA is making will provide a solid foundation for recruitment and for responsibly managing our user fee resources, Scott Gottlieb, Commissioner of the U.S. Food and Drug Administration said at the beginning of the week.
July 21, 2017
Diplomat to distribute Puma Biotechnology’s new cancer drug
Diplomat Pharmacy will distribute Puma Biotechnology’s new product, Nerlynx, a kinase inhibitor approved by the US Food and Drug Administration (FDA).